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Veillonella spp. rarely cause infections in humans. We
report a case of Veillonella endocarditis documented by
isolating a slow-growing, gram-negative microbe in blood
cultures. This microbe was identified as the newly recog-
nized species Veillonella montpellierensis (100% homolo-
gy) by 16S RNA gene sequence analysis.
V
eillonella are anaerobic, gram-negative cocci, part of
the normal flora of the mouth, gastrointestinal tract,
and vaginal tract. Veillonella dispar,  V. atypica, and V.
parvula have been cultured from human specimens. They
are infrequently isolated in human infections. Rarely,
Veillonella species have been the only etiologic agents
identified in serious infections such as meningitis,
osteomyelitis, prosthetic joint infection, pleuropulmonary
infection, endocarditis, and bacteremia. A new species, V.
montpellierensis, has recently been isolated from the gas-
tric fluid of a newborn and from the amniotic fluid of 2
women (1). Its pathogenic role is still debated.
The Study
A 75-year-old woman was admitted to the intensive
care unit with septic shock. She had a history of diabetes
mellitus. A cardiac murmur had been noted 8 years earlier
but was not investigated further. On physical examination,
the patient had aortic and mitral murmur. Reagent strip for
urinalysis detected leukocytes and nitrites. After 3 blood
cultures and urinalysis, the patient was treated for septic
shock secondary to upper urinary tract infection with cef-
triaxone, 2 g/day intravenously. The patient’s condition
rapidly improved with antimicrobial drugs and dopamine.
Three days after admission, she was afebrile and hemody-
namically stable; she was transferred to the urology depart-
ment for acute pyelonephritis, which had not been
confirmed by computed tomographic (CT) scan. Urine cul-
ture yielded Gardnerella vaginalis. Chest radiograph
showed a patchy density of the right inferior pulmonary
lobe confirmed by chest CT scan that suggested either
pneumonia or neoplasia. On day 6, a transesophageal
echocardiograph, performed because of the cardiac mur-
mur, showed oscillating intracardiac masses on the aortic
and mitral valves. Because the blood cultures were still
negative, we determined that the patient had culture-nega-
tive endocarditis and replaced ceftriaxone with amoxi-
cillin, 12 g/day for 6 weeks, in addition to gentamicin, 3
mg/kg/day for 3 weeks. On day 26, another trans-
esophageal echocardiograph was performed and showed
that the vegetation on the aortic valve had disappeared and
the mitral vegetation was greatly reduced. The patient was
discharged after 42 days of antimicrobial drug treatment,
and follow-up was not possible.
On day 14 after sampling, 2 of 3 anaerobic blood cul-
tures (automated blood culture BACTEC 9240 system
(Becton Dickinson, Le Pont de Claix, France) yielded a
slow-growing, gram-negative microbe. Blood was subcul-
tured onto Columbia agar with 5% sheep blood (Mérieux,
Marcy l’Etoile, France) under 5% CO2 and anaerobic
atmosphere and resulted in small colonies. This slow-
growing microbe was lost after 2 subcultures, and no iso-
late is available for further description. The isolate
retrieved in the blood culture was identified by 16S rRNA
gene sequence analysis. The template DNA was prepared
from a few colonies that were isolated on the blood agar
incubated anaerobically. DNA was extracted by using
Fastprep DNA extraction kit (Ozyme, St Quentin en
Yvelines, France) according to the manufacturer’s recom-
mendations and was subjected to polymerase chain reac-
tion (PCR) targeting the 16S rRNA gene as previously
described (2). Sequencing the PCR product (2) showed a
1,531-nucleotide sequence. This sequence shared 100%
homology with that of V. montpellierensis (GenBank
accession no. AY244769) and was already reported
(GenBank accession no. AY244769) in a previous article
(3). In this article, the isolated Veillonella strain (that was
isolated from our patient) was first identified as “candida-
tus V. atypica” since the sequencing of the amplicon dis-
closed 94% sequence similarity with that of V. atypica (3).
V. montpellierensis had not yet been described. PCR con-
tamination was unlikely since this organism had never
been amplified in our laboratory and negative controls
remained negative.
Conclusions
According to the modified Duke criteria (4), our patient
had definite endocarditis. Anaerobic microbes do not com-
monly cause endocarditis (5). Most cases of anaerobic
endocarditis are caused by anaerobic cocci,
Propionibacterium acnes, and Bacteroides fragilis group
(5). We describe the seventh reported case of well-docu-
mented infectious endocarditis in which a Veillonella
species was the sole pathogen and the first due to V. mont-
pellierensis. Characteristics of the 7 Veillonella endocardi-
tis patients are summarized in the Table. Five of them
fulfilled the Duke modified criteria for definite endocardi-
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reported cases of Veillonella endocarditis were due to
either V. dispar (9,10), V. parvula (11), or V. alcalescens
(6–8), currently considered V. parvula (12). One patient
had no history of fever (7), and 1 patient had no preexist-
ing valvular disease (8). Five patients had an infected
mitral valve; 4 of the 5 had prosthetic valves. Our patient
had mitral and aortic endocarditis. All patients had positive
blood culture except 2, for whom the diagnosis was made
by culturing the valve (6,11). Veillonella spp. had also been
isolated from intravenous drug users with polymicrobial
endocarditis (13); V. parvula was isolated from a lung
abscess in a patient with echocardiographic vegetations,
but blood cultures were negative (14). We could not test
the susceptibility of the organism because the bacterium
was lost on subculture. In treating infections with
Veillonella species, penicillin has been the antimicrobial
agent of choice (10). However, recent studies found a
notably high resistance to penicillin G (MIC >2µg/mL)
(15). These penicillin G–resistant isolates showed general-
ly reduced susceptibility to ampicillin or amoxicillin but
remained susceptible to amoxicillin and clavulanate (15).
We treated our patient for culture-negative endocarditis
with amoxicillin. As the clinical state of our patient
improved, we did not change antimicrobial agents.
Our isolate has recently been compared with 3 other
isolates and classified as a new Veillonella species named
V. montpellierensis by Jumas-Bilak et al. (1). We demon-
strate here that V. montpellierensis is pathogenic for
humans and may be included as a new agent of endocardi-
tis caused by fastidious pathogens. 
We report here the seventh case of endocarditis due to
Veillonella  spp. identified by PCR amplification and
sequencing of 16S rDNA gene and the first case of endo-
carditis due to V. montpellierensis. This case reemphasizes
the usefulness of molecular methods in identifying fastidi-
ous microorganisms and in describing new clinical entities
(3).
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